You searched for "intravitreal"
VIBIM Study: One-year results of treatment of DME with aflibercept using TnE
5 October 2020
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...
Insights in resistant diabetic macular oedema
5 August 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Autofluorescence patterns in subretinal haemorrhages associated with neovascular age-related macular degeneration
2 August 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The aim of this retrospective study was to describe the surgical results and fundus autofluorescence (FAF) patterns occurring in sub-macular haemorrhage (SMH) of duration <60 days in age-related macular degeneration (AMD). Notes from 39 eyes of 39 patients with SMH,...
IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
1 August 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...
Cytokine levels in vitreous fluid in patients with pathological myopia
1 April 2020
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
Pathological myopia (PM) is a leading cause of irreversible visual impairment worldwide, and efforts are dedicated to the study of its underlying mechanisms. Axial extension of the eyeball is regulated via a cascade of biochemical molecules that are initiated in...
Variability between handheld fundus cameras
3 January 2025
| Nishita Patel
|
EYE - Glaucoma
Handheld fundus cameras offer the potential of enhancing opportunities for telemedicine diagnosis of glaucoma, especially in underserved settings, as they are less bulky, inexpensive and don’t require skilled personnel compared to traditional table-mounted retinal cameras. This study aimed to compare...
Treatment of diabetic macular oedema
1 June 2014
| Samantha S Mann
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...Protecting retinal ganglion cells
1 August 2017
| Sofia Rokerya
|
EYE - Glaucoma
Glaucoma is considered to be a heterogeneous group of conditions giving retinal ganglion cells (RGC) damage. Lowering intraocular pressure (IOP) reduces the risk of progressive RGC loss in glaucoma. Regeneration of the optic nerve has been shown to restore some...
An update on inherited retinal disorders (part 2): Approaches to therapy for IRDs
1 December 2016
| Stacey Strong, Michel Michaelides (Prof)
|
EYE - Vitreo-Retinal
Part 1 of this topic can be found here There are currently no proven cures for inherited retinal disease (IRD). However, multiple avenues of research are being investigated to better understand disease mechanisms and trial potential therapies that may slow...
The results of the last survey Dec21
1 December 2021
| Amar Alwitry
|
EYE - Cataract, EYE - Refractive, EYE - Vitreo-Retinal, EYE - General
Consent is a hot topic at the moment and the publication of the GMC Guidance on Consent [1] has rightfully refocussed our attention on it. Consent practices vary wildly and have been the subject of many of these surveys. Once...
Strategies for managing neovascular AMD and DMO in routine clinical care
1 October 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...